NETRIS Pharma is developping a pipeline of drugs targeting different Dependance Receptors / Ligands.

By using several in vivo models of cancerogenesis in mici, NETRIS Pharma has shown that drug candidates targeting the various ligands of dependence receptors inhibits tumor growth and metastasis development.

These candidates are at various stages of development: from lead identification to clinical development.

NETRIS Pharma puts intellectual property at the center of its strategy.

The company holds worldwide exclusive rights and patents on major aspects of its activity and development.

Contact Us